Anchor Line Partners, LLC and Northwood Investors, LLC secures 98,500 s/f lease Stoke Therapeutics at 245 Fifth Ave.

Waltham, Ma Anchor Line Partners, LLC and Northwood Investors, LLC have secured a long-term lease with biotechnology company Stoke Therapeutics at 245 Fifth Ave. Stoke plans to relocate to its new 98,500 s/f headquarters when the company’s current lease in Bedford, Mass. ends in late 2026.

Stoke is dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen as a first-in-class potential disease-modifying treatment for Dravet syndrome. Dravet syndrome is a severe neurodevelopmental disease that is characterized by recurrent seizures as well as significant cognitive and behavioral impairments.

Stoke established its first headquarters in Bedford in 2015. Zorevunersen was discovered in Bedford, and since then, the company has advanced zorevunersen through early clinical testing into late-stage development. The company is actively preparing to commercialize its first potential new medicine in the United States and is expanding its research into additional medicines using its proprietary technology platform.

“Stoke is on an important growth trajectory as we prepare to commercialize a first-in-class potential new medicine to treat Dravet syndrome, while also broadening our research efforts to identify more new medicines for severe diseases,” said Ian Smith, chief executive officer and director of Stoke Therapeutics. “This new Waltham site will help foster our culture of teamwork and collaboration that is essential to innovation and our work to deliver life-changing medicines for patients.”

“While the national life sciences market has moderated, Waltham and the greater Route 128 corridor continue to prove their resilience as they support the biotech industry,” said Andrew Maher, co-founder and manager partner, Anchor Line Partners. 

“This lease reflects the continued strength of the Greater Boston life sciences market and our commitment to delivering best-in-class environments that meet the evolving needs of innovative companies and their employees.”

Waltham has emerged as one of the most compelling suburban life sciences hubs in the country, offering scale, talent and connectivity outside the urban core. The city and property offer immediate access to Route 128/I-95, I-90 and Route 2, making it a prime location for companies seeking operational efficiency and access to top talent. The property is LEED Gold and WiredScore Platinum certified, reinforcing the campus’s commitment to sustainability and connectivity. The building’s modern infrastructure and flexible lab-ready design made it a strategic fit for Stoke’s next phase of expansion.

The Cushman & Wakefield team of Mitch Perez, Connor Barnes and Michael Weiss represented Stoke in the transaction. Michael O’Leary and Duncan Gratton, also of Cushman & Wakefield, handle leasing efforts at 245 Fifth Ave..

This new lease exemplifies Anchor Line Partners’ expertise in the life sciences sector and its focus on tenant satisfaction, long-term value creation and market-driven development strategy.